Hu Qiaohong, Zeng Zeng, Zhang Yuanbiao, Fan Xiaoming
Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Front Oncol. 2023 Jan 4;12:926810. doi: 10.3389/fonc.2022.926810. eCollection 2022.
To evaluate the efficacy of ultrasound-guided percutaneous microwave ablation (PMA) combined with portal vein embolization (PVE) for planned hepatectomy.
We retrospectively reviewed data of 18 patients with multiple right liver tumors or hilar tumor of liver invades the surrounding tissue and insufficient future liver remnant (FLR) for hepatectomy from July 2015 to March 2017. Ultrasound-guided PMA was performed by using PMCT cold circulation microwave treatment apparatus. PVE was performed after PMA. The increase of FLR was evaluated by computed tomography (CT) 6-22 days after PVE. The proportion of FLR, increase in the amplitude of FLR, procedure-related complications, perioperative morbidity and mortality, and overall survival (OS) rates, the median survival time were analyzed.
The median volume of FLR before PMA and PVE was 369.7 ml (range: 239.4-493.1 ml). After a median waiting period of 11.5 days (range: 6-22 days), the median volume of FLR was increased to 523.4 ml (range: 355.4-833.3 ml). The changes in FLR before and after PMA and PVE were statistically significant (<0.001). No serious perioperative complications or mortality were found. After a median follow-up time of 51.0 months (range: 2-54 months), the 6-month, 1-year, 2-year, 3-year and 4-year survival rates were 88.9%, 72.2%, 44.4%, 33.3%, 22.2%, respectively, and the median survival time was 15.0 ± 7.1 months.
PMA combined with PVE increases FLR rapidly, avoids touching malignant tumors, and produces fewer procedure-related complications. It appears safe and efficacious for planned hepatectomy.
评估超声引导下经皮微波消融(PMA)联合门静脉栓塞(PVE)用于计划性肝切除术的疗效。
回顾性分析2015年7月至2017年3月期间18例右肝多发肿瘤或肝门部肿瘤侵犯周围组织且未来肝残余量(FLR)不足行肝切除术的患者资料。采用PMCT冷循环微波治疗仪进行超声引导下PMA。PMA后行PVE。在PVE后6 - 22天通过计算机断层扫描(CT)评估FLR的增加情况。分析FLR的比例、FLR增幅、手术相关并发症、围手术期发病率和死亡率、总生存率(OS)以及中位生存时间。
PMA和PVE前FLR的中位体积为369.7 ml(范围:239.4 - 493.1 ml)。经过中位11.5天(范围:6 - 22天)的等待期后,FLR的中位体积增加至523.4 ml(范围:355.4 - 833.3 ml)。PMA和PVE前后FLR的变化具有统计学意义(<0.001)。未发现严重的围手术期并发症或死亡病例。经过中位51.0个月(范围:2 - 54个月)的随访,6个月、1年、2年、3年和4年生存率分别为88.9%、72.2%、44.4%、33.3%、22.2%,中位生存时间为15.0±7.1个月。
PMA联合PVE可快速增加FLR,避免触碰恶性肿瘤,且手术相关并发症较少。对于计划性肝切除术而言,其似乎安全有效。